Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections

NCT02959957 is registered in ClinicalTrials.gov with Håkan Hanberger as lead sponsor.

NCT NCT02959957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections
Lead sponsor
Håkan Hanberger
Phase
Phase 4
Overall status
Completed
Start date
May 20, 2016
Completion date
August 31, 2019
Enrollment
157 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

urinary tract infections